Royal London Asset Management Ltd. Buys 2,073 Shares of Illumina, Inc. (NASDAQ:ILMN)

Royal London Asset Management Ltd. raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 3.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 67,155 shares of the life sciences company’s stock after purchasing an additional 2,073 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Illumina were worth $8,974,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. WCM Investment Management LLC lifted its position in Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after purchasing an additional 867,673 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Illumina by 0.8% in the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company’s stock valued at $454,617,000 after purchasing an additional 27,618 shares during the last quarter. Geode Capital Management LLC lifted its position in Illumina by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after purchasing an additional 48,018 shares during the last quarter. Janus Henderson Group PLC lifted its position in Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after purchasing an additional 625,245 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Illumina by 4.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock valued at $164,334,000 after acquiring an additional 54,319 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 3.4 %

NASDAQ ILMN opened at $87.66 on Friday. Illumina, Inc. has a 12 month low of $80.18 and a 12 month high of $156.66. The stock has a market cap of $13.89 billion, a P/E ratio of -11.41, a P/E/G ratio of 1.60 and a beta of 1.17. The stock’s fifty day moving average price is $108.20 and its 200-day moving average price is $128.27. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ILMN shares. Piper Sandler upped their target price on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Guggenheim decreased their target price on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday, February 7th. Stephens restated an “overweight” rating and set a $156.00 target price on shares of Illumina in a report on Tuesday, March 11th. TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and decreased their target price for the company from $177.00 to $140.00 in a report on Friday, February 7th. Finally, Citigroup decreased their target price on Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.